Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2

Cancer Letters

Volumn 310, Issue 2, 2011, Pages 188-197

  Ahn, Jun Ho ^a   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

Author keywords

Apoptosis; Autophagy; Multi drug resistance; PP2; Src tyrosine kinase inhibitor

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BECLIN 1; CASPASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; RAF PROTEIN; TYROSINE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVATION; GROWTH INHIBITION; INHIBITION KINETICS; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; G1 PHASE; MICE; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 80051696767     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.034     Document Type: Article

References (47)

1. de Grouw E.P., Raaijmakers M.H., Boezeman J.B., van der Reijden B.A., van de Locht L.T., de Witte T.J., Jansen J.H., Raymakers R.A. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-cells. Leukemia 2006, 20:750-754.
2. Wu C.P., Calcagno A.M., Ambudkar S.V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 2008, 1:93-105.
3. Moretti L., Yang E.S., Kim K.W., Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist. Update. 2007, 10:135-143.
4. Kim K.W., Hwang M., Moretti L., Jaboin J.J., Cha Y.I., Lu B. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 2008, 4:659-668.
5. Chen N., Karantza-Wadsworth V. Role and regulation of autophagy in cancer. Biochim. Biophys. Acta 2009, 1793:1516-1523.
6. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. MTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
7. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27:2278-2287.
8. Eum K.-H., Lee M. Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras transformed NIH3T3 cells. Mol. Cells 2010, 31:231-238.
9. Eisenberg-Lerner A., Bialik S., Simon H.U., Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009, 16:966-975.
10. Mishima Y., Terui Y., Mishima Y., Taniyama A., Kuniyoshi R., Takizawa T., Kimura S., Ozawa K., Hatake K. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci. 2008, 99:2200-2208.
11. Bjorge J.D., Jakymiw A., Fujita D.J. Selected glimpses into the activation and function of Src kinase. Oncogene 2000, 19:5620-5635.
12. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
13. Wu Z., Chang P.-C., Yang J.C., Chu C.-Y., Wang L.-Y., Chen N.-T., Ma A.-H., Desai S.J., Lo S.H., Evans C.P., Lam K.S., Kung H.-J. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 2010, 1:40-49.
14. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 1996, 271:695-701.
15. 2. J. Biol. Chem. 2004, 279:48692-48701.
16. Ahn J.-H., Kim Y.-K., Lee M. Decreased interaction of Raf-1 with its negative regulator Spry2 as a mechanism for acquired drug resistance. Biomol. Ther. 2011, 19:174-180.
17. Lee M., Ahn J.-H., Eum K.-H. The differences in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res. Treat. 2009, 41:93-99.
18. George J.A., Chen T., Taylor C.C. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005, 65:10381-10388.
19. Ahn J.-H., Eum K.-H., Lee M. The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts. Mol. Cell. Biochem. 2009, 332:189-197.
20. Meijer A.J., Codogno P. Autophagy: regulation and role in disease. Crit. Rev. Clin. Lab. Sci. 2009, 46:210-240.
21. Seglen P.O., Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. USA 1982, 79:1889-1892.
22. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
23. Babchia N., Calipel A., Mouriaux F., Faussat A.M., Mascarelli F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest. Ophthalmol. Vis. Sci. 2010, 51:421-429.
24. Zheng B., Jeong J.H., Asara J.M., Yuan Y.Y., Granter S.R., Chin L., Cantley L.C. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33:237-247.
25. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
26. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
27. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
28. Kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell. Biol. 2007, 9:218-224.
29. Milano V., Piao Y., LaFortune T., de Groot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther. 2009, 8:394-406.
30. Chang Y.M., Bai L., Liu S., Yang J.C., Kung H.J., Evans C.P. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 27:6365-6375.
31. Toyoshima H., Huter T. P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74.
32. Collado M., Medema R.H., Garcia-Cao I., Dubuisson M.L., Barradas M., Glassford J., Rivas C., Burgering B.M., Serrano M., Lam E.W. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J. Biol. Chem. 2000, 275:21960-21968.
33. Fujiwara K., Daido S., Yamamoto A., Kobayashi R., Yokoyama T., Aoki H., Iwado E., Shinojima N., Kondo Y., Kondo S. Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J. Biol. Chem. 2008, 283:388-397.
34. Klionsky D.J., Meijer A.J., Codogno P. Autophagy and p70S6 kinase. Autophagy 2005, 1:59-60.
35. Balakumaran B.S., Herbert J.T., Febbo P.G. MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy. Autophagy 2010, 6:281-282.
36. Um S.H., Frigerio F., Watanabe M., Icard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
37. Scott R.C., Schuldiner O., Neufeld T.P. Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell 2004, 7:167-178.
38. Pause A., Belsham G.J., Gingras A.C., Donzé O., Lin T.A., Lawrence J.C.J., Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 1994, 371:762-767.
39. Karbowniczek M., Cash T., Cheung M., Robertson G.P., Astrinidis A., Henske E.P. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 2004, 279:29930-29937.
40. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
41. Maiuri M.C., Criollo A., Tasdemir E., Vicencio J.M., Tajeddine N., Hickman J.A., Geneste O., Kroemer G. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007, 3:374-376.
42. Bassik M.C., Scorrano L., Oakes S.A., Pozzan T., Korsmeyer S.J. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J. 2004, 23:1207-1216.
43. Poruchynsky M.S., Wang E.W., Rudin C.M., Blagosklonny M.V., Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998, 58:3331-3338.
44. Wang H.-G., Miyashita T., Takayama S., Sato T., Torigoe T., Krajewski S., Tanaka S., Lawrence Hovey I., Troppmair J., Rapp U.R., Reed J.C. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994, 9:2751-2756.
45. Kroemer G., Levine B. Autophagic cell death: the story of a misnomer. Nat. Rev. Mol. Cell Biol. 2008, 9:1004-1010.
46. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
47. Chen S., Rehman S.K., Zhang W., Wen A., Yao L., Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim. Biophys. Acta 2010, 1806:220-229.